Metabolic Diseases/Disorders

top of page

Roche’s GLP‑1/GIP receptor agonist CT‑388 demonstrated strong efficacy in patients with obesity | iPharmaCenter

ipharmaservices

Jan 27

Sun Pharma obtains DCGI nod to produce generic semaglutide injection for weight management in India | iPharmaCenter

Badari Andukuri

Jan 25

Aspect Biosystems Deepens Novo Nordisk Alliance to Advance Curative Cell Therapies for Diabetes | iPharmaCenter

ipharmaservices

Jan 21

Lilly Takes on Novo Nordisk with Head-to-Head Data Comparing Zepbound and Wegovy | iPharmaCenter

ipharmaservices

Dec 6, 2024

Tirzepatide significantly reduced the risk of progression to type 2 diabetes in adults with prediabetes and obesity, preventing most from developing the disease over 176 weeks | iPharmaCenter

ipharmaservices

Nov 14, 2024

Pfizer decides to continue development of GLP agonist Danuglipron | iPharmaCenter

ipharmaservices

Jul 16, 2024

Obesity News | Overweight | Treatments |Updates | iPharmaCenter

Obesity News | Overweight | Treatments |Updates | iPharmaCenter

Obesity News | Overweight | Treatments |Updates | iPharmaCenter

ipharmaservices

Aug 21, 2023

Diabetes mellitus News | iPharmaCenter

Diabetes mellitus News | iPharmaCenter

Diabetes mellitus News | iPharmaCenter

ipharmaservices

Mar 19, 2023

NASH News | Updates | Liver disease

NASH News | Updates | Liver disease

NASH News | Updates | Liver disease

ipharmaservices

May 30, 2022

bottom of page